Immunosuppressive
PreclinicalSmall molecule
Chiesi Farmaceutici S.p.A.Immunosuppressive is one of 108 small molecule programs targeting Metabolic Syndrome. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
107
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Kidney Transplant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immunosuppressive. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company